Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

86%

6 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

5(71.4%)

Phase 2

1(14.3%)

Phase 4

1(14.3%)

7Total

Phase 3(5)

Phase 2(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03490123Phase 4Completed

Evaluation of an Intensive 3-round MDA Strategy Towards Yaws Eradication

Role: lead

NCT03676140Phase 3Completed

Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )

Role: lead

NCT03664063Phase 2Completed

PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )

Role: lead

NCT01955252Phase 3Completed

Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea

Role: lead

NCT02605720Phase 3Completed

Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns

Role: lead

NCT01785979Phase 3Withdrawn

Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly

Role: lead

NCT01382004Phase 3Completed

Single-dose Azithromycin for the Treatment of Yaws

Role: lead

All 7 trials loaded